Advancing First & Best-In-Class mRNA Vaccines & Therapies from Concept to Commercialisation with Targeted Delivery, Better Tolerability & Clinical Safety to Combat All Diseases

28th-30th January, 2025 | Frankfurt, Germany

Copy of 47392 - Industry News (1)

Europe’s Largest Industry-Led & Dedicated Gathering for mRNA Leaders

With GSK’s €1.4Bn investment into acquiring CureVac’s infectious disease pipeline, Moderna and BioNTech’s initiation of personalised cancer vaccine trials, and the emergence of novel mRNA applications in protein replacement therapy, gene editing and in vivo cell engineering, the mRNA industry is observing huge value R&D opportunities that will open the floodgates towards clinical and market approval in 2025.

The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines.

Whether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran, with two dedicated tracks of content spanning discovery through commercialisation, this forum will equip you with the know-how and connections to make rapid advances in your work with partnering and collaborative networking opportunities spread throughout.

Assembling 200+ mRNA enthusiasts from across Europe, Asia and the globe, this is your one-stop-shop to gain unparalleled overview of cutting-edge R&D innovations, whilst diving deep into end-to-end development strategy to revolutionise the next wave of mRNA medicines towards clinical reality.

Copy of mRNA EU Sponsor Logos (2)

This is a great opportunity to share current thinking on mRNA therapeutics with regulatory and industry partners from across Europe."

Shirley Hopper, Deputy Director National Licensing Strategy, Medicines and Healthcare Products Regulatory Agency (MHRA)

Among Our 40+ World-Class Speaker Faculty:

Adèle Schmitt

Expert Scientist

GSK

Alexander Zehnder

Chief Executive Officer

CureVac

Andreas Kuhn

Sen. Vice President RNA Biochemistry & CMC Development

BioNTech SE

Marie Caby-Tosi

European Economic Area/ United Kingdom Qualified Person for Pharmacovigilance

Moderna

Pierre Wils

Global Scientific Advisory Lead

mRNA Centre of Excellence, Sanofi

Shirley Hopper

Deputy Director National Licensing Strategy

Medicines & Healthcare products Regulatory Agency

Verena Mummert

Director - Alliance Management

Ethris

Vincent Serra

Chief Scientific & Operating Officer

Neovacs

Attending Companies Include:

39
38
37
36
35
34
32
33
41
42
40
46
Copy of mRNA EU Sponsor Logos (4)

"The mRNA-Based Therapeutics Summit Europe, builds on scientific achievements in this evolving field, brings together stakeholders from various functions to discuss the challenges and opportunities to maximizing the impact of mRNA medicine on people’s health."

Maren von Fritschen, Head of Regulatory Policy Europe, Moderna

Official 2025 Partners

Expertise Partners

Thermo_Fisher_Scientific_Logo
Recibio